Screener
Veradermics MANE Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,925 | $11,447 |
| General and administrative | 8,937 | 1,468 |
| Total operating expenses | 29,862 | 12,915 |
| Loss from operations | (29,862) | (12,915) |
| Other income: | ||
| Interest income | 2,481 | 482 |
| Other income | 149 | 33 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's total operating expenses?
- Veradermics (MANE) reported total operating expenses of $29.86M in Q1 2026.
- How has Veradermics's total operating expenses changed year-over-year?
- Veradermics's total operating expenses increased by 131.2% year-over-year, from $12.92M to $29.86M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Veradermics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude